Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Orly Lipsitz

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
CNS Drugs|November 18, 2021
Molecular Mechanisms of Psilocybin and Implications for the Treatment of DepressionSusan Ling, Felicia Ceban, Leanna M W Lui, et al.
Obesity (Silver Spring, Md.)|October 6, 2020
Antidepressant Medications and Weight Change: A Narrative ReviewHartej Gill, Barjot Gill, Sabine El-Halabi, et al.
Journal of Affective Disorders|June 23, 2021
Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?Roger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 22, 2021
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case SeriesOrly Lipsitz, Joshua D Di Vincenzo, Nelson B Rodrigues, et al.
Journal of Affective Disorders|July 5, 2021
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic reviewJason Ng, Joshua D Rosenblat, Leanna M W Lui, et al.
Journal of Affective Disorders|May 30, 2021
Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countriesYena Lee, Leanna M W Lui, David Chen-Li, et al.
Journal of Affective Disorders|July 31, 2021
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamineRoger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
CNS Drugs|September 13, 2022
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic ReviewNiloufar Pouyan, Zahra Halvaei Khankahdani, Farnaz Younesi Sisi, et al.
Bipolar Disorders|May 15, 2020
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorderRoger S McIntyre, Orly Lipsitz, Nelson B Rodrigues, et al.
Journal of Sleep Research|June 17, 2021
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
CNS Drugs|November 18, 2021
Molecular Mechanisms of Psilocybin and Implications for the Treatment of DepressionSusan Ling, Felicia Ceban, Leanna M W Lui, et al.
Obesity (Silver Spring, Md.)|October 6, 2020
Antidepressant Medications and Weight Change: A Narrative ReviewHartej Gill, Barjot Gill, Sabine El-Halabi, et al.
Journal of Affective Disorders|June 23, 2021
Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?Roger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|January 22, 2021
Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case SeriesOrly Lipsitz, Joshua D Di Vincenzo, Nelson B Rodrigues, et al.
Journal of Affective Disorders|July 5, 2021
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic reviewJason Ng, Joshua D Rosenblat, Leanna M W Lui, et al.
Journal of Affective Disorders|May 30, 2021
Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countriesYena Lee, Leanna M W Lui, David Chen-Li, et al.
Journal of Affective Disorders|July 31, 2021
The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamineRoger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
CNS Drugs|September 13, 2022
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic ReviewNiloufar Pouyan, Zahra Halvaei Khankahdani, Farnaz Younesi Sisi, et al.
Bipolar Disorders|May 15, 2020
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorderRoger S McIntyre, Orly Lipsitz, Nelson B Rodrigues, et al.
Journal of Sleep Research|June 17, 2021
Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Pageof 6